<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088295</url>
  </required_header>
  <id_info>
    <org_study_id>MATH</org_study_id>
    <nct_id>NCT01088295</nct_id>
  </id_info>
  <brief_title>HIV and Fat Accumulation</brief_title>
  <acronym>MATH</acronym>
  <official_title>Metabolic Abnormalities, Telmisartan and HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California HIV/AIDS Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to see whether fat accumulation either under the skin or in the
      body's organs, for example, the liver, improves in men and women who take a drug called
      telmisartan. The investigators will be looking at how the amount of fat in the body changes
      when HIV-positive persons on effective anti-HIV therapy take telmisartan. The investigators
      will be using a CT scan to make this comparison. Telmisartan is not an HIV medication. It is
      a medication used to treat blood pressure, but has been shown to decrease fat in the organs
      in people both with and without high blood pressure. The study involves 8 visits over a
      period of about 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Change in Visceral Adipose Tissue (VAT) Volume</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Telmisartan</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40mg po daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>Micardis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive men and women 18 years and older

          -  HIV-1 infection as documented by ELISA and confirmed by Western blot or plasma HIV-1
             RNA &gt;2000 on two occasions

          -  Documented central fat accumulation

          -  HIV RNA documented to be less than 50 copies/mL at screening and undetectable by assay
             of choice for at least 12 weeks prior to entry

          -  Current antiretroviral therapy with a suppressive, highly active antiretroviral
             regimen.

          -  Systolic BP &gt;115mmHg.

          -  Ability and willingness to provide informed consent

        Exclusion Criteria:

          -  Pregnancy (current or within the last 6 months) or nursing

          -  Uncontrolled hypertension

          -  Prohibited concomitant medications

          -  Subjects with untreated hyperlipidemia must be willing to abstain from initiating
             therapy for the 24 week duration fo the study.

          -  Subjects undergoing treatment for diabetes with oral hypoglycemic agents must be
             willing to remain on their current dose of insulin sensitizing agents for the duration
             of the study.

          -  Known, untreated renal artery stenosis

          -  Unstable coronary artery disease/angina or decompensated congestive heart failure.

          -  Any history of intolerance to any member of the angiotensin receptor blocker class of
             agents.

          -  Need for ongoing potassium supplementation.

          -  Screening laboratory values as follows ANC (absolute neutrophil count) &lt;750 cells/mm3
             Hemoglobin &lt;10 gm/dL ClCr (creatinine clearance)&lt; 30 ml/min (estimated by
             Cockcroft-Gault equation) AST (aspartate aminotransferase) or ALT (alanine
             aminotransferase) &gt; 3 x ULN (upper limit of normal)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Lake, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>January 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2013</results_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jordan E. Lake M.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Metabolic</keyword>
  <keyword>HIV</keyword>
  <keyword>Fat accumulation</keyword>
  <keyword>AIDS</keyword>
  <keyword>Metabolic abnormalities in HIV infection</keyword>
  <keyword>HIV Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited between May and October 2010 at the UCLA CARE Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan</title>
          <description>Telmisartan 40mg po daily for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan</title>
          <description>Telmisartan 40mg po daily for 24 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Change in Visceral Adipose Tissue (VAT) Volume</title>
        <description>VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>as-treated analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan</title>
            <description>Telmisartan 40mg po daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Visceral Adipose Tissue (VAT) Volume</title>
          <description>VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography</description>
          <population>as-treated analysis</population>
          <units>cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" lower_limit="-29.5" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Telmisartan</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordan E. Lake, M.D., M.Sc.</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>(310)557-1891</phone>
      <email>jlake@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

